ClinicalTrials.gg
Active, not recruitingNCT05410418Updated Oct 28, 2026Results posted

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

A Phase 2 interventional study of Mosunetuzumab and Polatuzumab vedotin in Lymphoma, Follicular and Follicular Lymphoma, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.

Enrollment
11th of 17
34 · median 42
Started
2022
with 5 others
Phase 2
11 of 17
7 open now
Primary completion
2025-09
later than 0 of 14 live
Registered
7th of 17
by date
Lead sponsor
2 of 17
Washington University School of Medicine

Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 11th largest by enrollment, is one of 6 that started in 2022, is one of 11 in phase 2, reaches primary completion later than 0 of the 14 other live ones, and was the 7th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About mosunetuzumab

mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing mosunetuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead. Polatuzumab vedotin is an antibody-drug conjugate that attaches to certain cancerous B cells and then delivers a drug specifically to those cells.

03

Conditions studied

  • Lymphoma, Follicular
  • Follicular Lymphoma

Keywords

  • lymphoma
  • follicular lymphoma
  • antibody-drug conjugate
  • B-NHL
  • B cell non-Hodgkin lymphoma
  • mosunetuzumab
  • polatuzumab vedotin
  • bispecific antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of follicular lymphoma grade 1-3A, stage II-IV by Ann Arbor criteria.
  • One or more of the following criteria (adapted from GELF criteria):

    • Any nodal or extranodal tumor mass with diameter > 7 cm
    • Involvement of at least 3 nodal sites, each with diameter > 3 cm
    • Presence of any systemic or B symptoms
    • Splenic enlargement with inferior margin below the umbilical line
    • Compression syndrome (e.g., ureteral, orbital, gastrointestinal)
    • Pleural or peritoneal serous effusion (irrespective of cell content)
    • Cytopenia(s) attributable to lymphoma
  • At least 18 years of age.
  • performance status ≤ 2
  • Adequate hematologic and organ function (unless due to underlying lymphoma per the investigator; see below), defined as follows:

    • ≥ 1,000/mcL
    • ≥ 75,000/mcL
    • ≥ 8 g/dL
    • Serum total ≤ 1.5 x IULN (or ≤ 3 x IULN for patients with Gilbert syndrome)
    • (SGOT)/ALT(SGPT) ≤ 3 x IULN
    • Serum creatinine ≤ 1.0 x IULN or ≥ 50 mL/min by Cockcroft-Gault
  • Patients with extensive bone marrow involvement by lymphoma and/or disease-related cytopenias (e.g., immune thrombocytopenia) may be enrolled if the following criteria are met:

    • Absolute neutrophil count ≥ 500/mcL
    • Platelet count ≥ 50,000/mcL without platelet transfusion within 14 days prior to the first dose of mosunetuzumab
    • Hemoglobin ≥ 7 g/dL without red blood cell transfusion within 7 days prior to the first dose of mosunetuzumab
  • The effects of mosunetuzumab on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate prior to study entry, for the duration of study treatment, for 3 months following the final dose of mosunetuzumab, for 9 months after the final dose of polatuzumab vedotin, and for 3 months after the final dose of tocilizumab, as applicable. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study treatment, for 6 months after the final dose of polatuzumab vedotin, and for 2 months after the final dose of tocilizumab, as applicable.
  • Ability to understand and willingness to sign an IRB approved written document (or that of legally authorized representative, if applicable).

Exclusion criteria

Exclusion Criteria:

  • Prior history of aggressive B cell lymphoma such as diffuse large B cell lymphoma or high-grade B cell lymphoma.
  • Known history of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents.
  • Known history of macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH).
  • Current or past history of CNS lymphoma.
  • Any prior systemic therapy for follicular lymphoma.
  • Treatment with radiotherapy within 2 weeks prior to the first dose of mosunetuzumab (otherwise one outside of the radiation field must remain).
  • Treatment with any anti-CD20 monoclonal antibody within 4 weeks of Day 1 of Cycle 1.
  • Current or recent history (within the last 6 months) of CNS disease, such as stroke, epilepsy CNS vasculitis, or serious progressive neurodegenerative disease, with symptoms.
  • Treatment with systemic medications, including but not limited to prednisone (> 20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1.

    * Note: The use of inhaled , mineralocorticoids for management of orthostatic hypotension, and single dose dexamethasone for nausea or B symptoms is permitted.

  • History of solid organ transplantation.
  • History of stem cell transplantation.
  • Prior treatment with chimeric antigen receptor T cell therapy within 30 days before Day 1 of Cycle 1.
  • History of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies (mAbs).
  • Known to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab formulation, including mannitol.
  • History of erythema multiforme, Grade ≥ 3 rash, or blistering following prior treatment with immunomodulatory derivatives.
  • Known active bacterial, viral, fungal, or other infection, or any major episode of infection requiring treatment with IV antibiotics within 1 week of Day 1 of Cycle 1.
  • Known or suspected chronic active Epstein-Barr virus (EBV) infection.
  • Current Grade > 1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease.
  • Active infection.

    * Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation

  • Active infection.

    * Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation

  • Known history of (HIV) positive status.
  • History of progressive multifocal leukoencephalopathy (PML).
  • Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a will be required during the study.

    * Patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study treatment or after the last dose until B cell recovery to the normal ranges.

  • Other that could affect compliance with the protocol or interpretation of results, with the exception of the following:

    • Any of the following malignancies previously curatively treated: carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal, or squamous cell skin cancer
    • Stage I melanoma, low grade, early stage localized prostate cancer, or any other previously treated malignancy that has been in remission without treatment for at least 2 years prior to enrollment
  • Active disease requiring treatment.
  • History of autoimmune disease, including, but not limited to, myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

    • Patients with a remote history of, or well-controlled autoimmune disease, with a treatment free interval from immunosuppressive therapy for 12 months may be eligible to enroll if judged to be safe by the investigator.
    • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone are eligible.
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with a history of disease-related immune thrombocytopenic purpura, or autoimmune hemolytic anemia may be eligible.
  • Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to, significant cardiovascular disease (e.g., Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm).
  • Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study.
  • Pregnant or lactating or intending to become pregnant during the study.

    * Women of must have 1 negative serum pregnancy test result (minimum sensitivity, 25 mIU/mL) within 7 days of initiating Cycle 1 Day 1 of therapy.

  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Mosunetuzumab and Polatuzumab Vedotin

    Patients receive CD3xCD20 bispecific antibody mosunetuzumab administered subcutaneously in combination with CD79b directed ADC polatuzumab vedotin administered intravenously. Mosunetuzumab and polatuzumab vedotin are given in combination for 6 cycles. Mosunetuzumab is given on Days 1, 8, and 15 of cycle 1 and then Day 1 thereafter, and polatuzumab vedotin is given on Day 1. After 6 cycles, patients continue on mosunetuzumab alone for 2 additional cycles. Patients undergo scans at the end of cycle 8, and if those scans show a complete response, patients will stop any further treatment and will enter follow-up. Patients with a partial response or stable disease on scans at the end of cycle 8 may receive up to 9 additional cycles of mosunetuzumab in the absence of disease progression or unacceptable toxicity. All cycles are planned to be 21 days.

    Drug: Mosunetuzumab · Drug: Polatuzumab vedotin

Interventions

  • Mosunetuzumab is administered subcutaneously using a "step-up" dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg.

    Also known as: RO7030816, BTCT4465A

  • Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.

    Also known as: RO5541077, DCDS4501A

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Response (CR) as Best Response

    CR determined by response to treatment by PET-CT at end of treatment per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: Through completion of treatment (estimated to be 1 year)

Secondary outcomes

  1. Number of Participants With Complete Response (CR)

    CR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)

  2. Number of Participants With Partial Response (PR)

    PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)

  3. Number of Participants With Partial Response (PR) as Best Response

    PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: Through completion of treatment (estimated to be 1 year)

  4. Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)

    CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)

  5. Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)

    CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: Through completion of treatment (estimated to be 1 year)

  6. Number of Participants With Stable Disease (SD)

    SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)

  7. Number of Participants With Stable Disease (SD) as Best Response

    SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: Through completion of treatment (estimated to be 1 year)

  8. Number of Participants With Progressive Disease (PD)

    PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)

  9. Number of Participants With Progressive Disease (PD) as Best Response

    PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: Through completion of treatment (estimated to be 1 year)

  10. Number of Participants With Complete Response (CR)

    CR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)

  11. Number of Participants With Partial Response (PR)

    PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)

  12. Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)

    CR and PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)

  13. Number of Participants With Stable Disease (SD)

    SD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)

  14. Number of Participants With Progressive Disease (PD)

    PD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

    Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)

  15. Time to First Response of Complete Response (CR) or Partial Response (PR)

    Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year).

    Time frame: Through completion of treatment (estimated to be 1 year)

  16. Time to First Complete Response (CR)

    Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)

    Time frame: Through completion of treatment (estimated to be 1 year)

  17. Frequencies and Grades of Treatment-emergent Adverse Events (TEAEs)

    Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).

  18. Rate of Treatment Discontinuation Due to Treatment-emergent Adverse Events (TEAEs)

    TEAEs are defined as adverse events that are possibly, probably, or definitely related to study treatment and occur on or after first dose of study treatment..

    Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).

  19. Percentage of Patients Requiring Any Tocilizumab Doses for Management of Cytokine Release Syndrome (CRS)

    Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.

    Time frame: Up to approximately 1 year and 3 days

  20. Number of Tocilizumab Doses Per Patient for Management of Cytokine Release Syndrome (CRS)

    Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.

    Time frame: Up to approximately 1 year and 3 days

  21. Progression-free Survival (PFS)

    Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.

    Time frame: At 24 months

  22. Progression-free Survival (PFS)

    Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.

    Time frame: At 48 months

  23. Overall Survival (OS)

    Overall survival is defined from the time from study enrollment to death from any cause.

    Time frame: At 24 months

  24. Overall Survival (OS)

    Overall survival is defined from the time from study enrollment to death from any cause.

    Time frame: At 48 months

  25. Duration of First Response of Complete Response (CR) or Partial Response (PR)

    Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)

    Time frame: Through completion of follow-up (estimated to be 6 years)

  26. Duration of First Complete Response (CR)

    Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)

    Time frame: Through completion of follow-up (estimated to be 6 years)

  27. Time to Next Treatment (TTNT)

    Time to next treatment (TTNT) initiation is defined as the time from study enrollment to the first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy, or immunotherapy) after completion of study treatment.

    Time frame: Through completion of follow-up (estimated to be 6 years)

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneMosunetuzumab and Polatuzumab Vedotin
Started34
Completed29
Not completed5
Withdrew: Adverse event3
Withdrew: Disease progression1
Withdrew: Inadequate response post cycle 2 pet scan1

Outcome measures

PrimaryNumber of Participants With Complete Response (CR) as Best Response

CR determined by response to treatment by PET-CT at end of treatment per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR) as Best Response
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Complete Response (CR) as Best Response30
SecondaryNumber of Participants With Complete Response (CR)

CR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Complete Response (CR)26
SecondaryNumber of Participants With Partial Response (PR)

PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Partial Response (PR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Partial Response (PR)2
SecondaryNumber of Participants With Partial Response (PR) as Best Response

PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Count of participants · Participants
Number of Participants With Partial Response (PR) as Best Response
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Partial Response (PR) as Best Response2
SecondaryOverall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)

CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)28
SecondaryOverall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)

CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)32
SecondaryNumber of Participants With Stable Disease (SD)

SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Stable Disease (SD)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Stable Disease (SD)0
SecondaryNumber of Participants With Stable Disease (SD) as Best Response

SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Count of participants · Participants
Number of Participants With Stable Disease (SD) as Best Response
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Stable Disease (SD) as Best Response1
SecondaryNumber of Participants With Progressive Disease (PD)

PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Progressive Disease (PD)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Progressive Disease (PD)1
SecondaryNumber of Participants With Progressive Disease (PD) as Best Response

PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Count of participants · Participants
Number of Participants With Progressive Disease (PD) as Best Response
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Progressive Disease (PD) as Best Response1
SecondaryNumber of Participants With Complete Response (CR)

CR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Complete Response (CR)20
SecondaryNumber of Participants With Partial Response (PR)

PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Partial Response (PR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Partial Response (PR)11
SecondaryOverall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)

CR and PR determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR)31
SecondaryNumber of Participants With Stable Disease (SD)

SD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Stable Disease (SD)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Stable Disease (SD)2
SecondaryNumber of Participants With Progressive Disease (PD)

PD determined by response to treatment by PET-CT after Cycle 2 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT.

Time frame:
After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Progressive Disease (PD)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Number of Participants With Progressive Disease (PD)1
SecondaryTime to First Response of Complete Response (CR) or Partial Response (PR)

Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year).

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Median · days
Time to First Response of Complete Response (CR) or Partial Response (PR)
daysMosunetuzumab and Polatuzumab Vedotin
Time to First Response of Complete Response (CR) or Partial Response (PR)42 (42 to 43)
SecondaryTime to First Complete Response (CR)

Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)

Time frame:
Through completion of treatment (estimated to be 1 year)
Reported as:
Median · days
Time to First Complete Response (CR)
daysMosunetuzumab and Polatuzumab Vedotin
Time to First Complete Response (CR)48.5 (42 to 165)
SecondaryFrequencies and Grades of Treatment-emergent Adverse Events (TEAEs)
Time frame:
Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
Reported as:
Count of participants · Participants
Frequencies and Grades of Treatment-emergent Adverse Events (TEAEs)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Grade 1/2 Anemia14
Grade 1/2 Eosinophilia1
Grade 3/4/5 Febrile neutropenia1
Grade 1/2 Ejection fraction decrease1
Grade 1/2 Tachycardia2
Grade 1/2 Palpitations1
Grade 1/2 Vertigo2
Grade 1/2 Conjunctivitis1
Grade 1/2 Eye pain1
Grade 1/2 Abdominal pain4
Grade 3/4/5 Abdominal pain1
Grade 1/2 Bloating2
Grade 1/2 Constipation15
Grade 3/4/5 Constipation1
Grade 1/2 Diarrhea14
Grade 3/4/5 Diarrhea3
Grade 1/2 Dry mouth1
Grade 1/2 Dyspepsia2
Grade 1/2 Gastroesophageal reflux disease2
Grade 1/2 GERD flare1
Grade 1/2 Nausea17
Grade 1/2 Vomiting6
Grade 1/2 Chills4
Grade 1/2 Fatigue18
Grade 1/2 Fever6
Grade 1/2 Bruise of L forearm at infusion site1
Grade 1/2 Flatulence1
Grade 1/2 Shakiness1
Grade 1/2 Infusion related reaction1
Grade 1/2 Infusion site extravasation1
Grade 1/2 Injection site reaction24
Grade 1/2 Malaise2
Grade 1/2 Pain2
Grade 1/2 Allergic reaction1
Grade 1/2 Tumor flare1
Grade 1/2 Enterocolitis infectious3
Grade 1/2 Eye infection1
Grade 1/2 Gallbladder infection1
Grade 1/2 Herpes simplex reactivation1
Grade 1/2 Rhinovirus1
Grade 1/2 Folliculitis1
Grade 1/2 Lung infection1
Grade 1/2 Sinusitis1
Grade 1/2 Skin infection1
Grade 1/2 Upper respiratory infection10
Grade 3/4/5 Upper respiratory infection1
Grade 1/2 Urinary tract infection1
Grade 1/2 Vaginal infection1
Grade 1/2 Fall1
Grade 1/2 Foot fracture1
Grade 1/2 Spider bite1
Grade 1/2 Alanine aminotransferase increased10
Grade 1/2 Alkaline phosphatase increased3
Grade 1/2 Aspartate aminotransferase increased9
Grade 1/2 Blood bilirubin increased4
Grade 1/2 Cholesterol high1
Grade 1/2 Creatinine increased5
Grade 1/2 Elevated TSH1
Grade 1/2 LDH increased18
Grade 1/2 Lymphocyte count decreased14
Grade 3/4/5 Lymphocyte count decreased15
Grade 1/2 Neutrophil count decreased6
Grade 3/4/5 Neutrophil count decreased8
Grade 1/2 Platelet count decreased4
Grade 3/4/5 Platelet count decreased1
Grade 1/2 Weight loss1
Grade 1/2 White blood cell decreased10
Grade 3/4/5 White blood cell decreased2
Grade 1/2 Hypercalcemia3
Grade 1/2 Hyperglycemia6
Grade 1/2 Hyperkalemia8
Grade 1/2 Hypernatremia1
Grade 1/2 Hypoalbuminemia2
Grade 1/2 Hypocalcemia3
Grade 1/2 Hypoglycemia2
Grade 1/2 Hypokalemia1
Grade 1/2 Hyponatremia5
Grade 1/2 Hypophosphatemia2
Grade 1/2 Hyperlipidemia1
Grade 1/2 Hyperphosphatemia1
Grade 1/2 Arthralgia4
Grade 1/2 Arthritis1
Grade 1/2 Back pain2
Grade 1/2 Bone pain2
Grade 1/2 Generalized muscle weakness2
Grade 1/2 Muscle weakness upper limb1
Grade 1/2 Left shoulder pain1
Grade 1/2 Right Achilles injury1
Grade 1/2 Myalgia6
Grade 3/4/5 Myelodysplastic syndrome1
Grade 1/2 Dizziness1
Grade 1/2 Headache10
Grade 1/2 Peripheral motor neuropathy1
Grade 1/2 Peripheral sensory neuropathy13
Grade 1/2 Tremor3
Grade 3/4/5 Vasovagal reaction1
Grade 3/4/5 Pregnancy loss1
Grade 1/2 Depression1
Grade 1/2 Insomnia4
Grade 1/2 Emotional lability1
Grade 1/2 Mood changes1
Grade 1/2 Hematuria2
Grade 1/2 Proteinuria2
Grade 1/2 Dysuria1
Grade 1/2 Urinary frequency1
Grade 1/2 Blood in semen1
Grade 1/2 Allergic rhinitis1
Grade 1/2 Cough6
Grade 1/2 Dyspnea2
Grade 1/2 Epistaxis1
Grade 1/2 Hiccups1
Grade 1/2 Hoarseness2
Grade 1/2 Hypoxia1
Grade 1/2 Nasal Congestion2
Grade 1/2 Pneumonitis2
Grade 1/2 Postnasal drip1
Grade 1/2 Pleurisy1
Grade 1/2 Rhinorrhea2
Grade 1/2 Sore throat1
Grade 1/2 Wheezing1
Grade 1/2 Alopecia2
Grade 1/2 Body odor1
Grade 1/2 Dry skin5
Grade 1/2 Pruritus5
Grade 1/2 Rash maculo-papular4
Grade 1/2 Poison Ivy1
Grade 1/2 Rash13
Grade 3/4/5 Rash1
Grade 1/2 Skin peeling4
Grade 1/2 Hair thinning2
Grade 1/2 Flushing2
Grade 1/2 Hot flashes1
Grade 1/2 Hypertension1
Grade 1/2 Hypotension5
Grade 1/2 Phlebitis1
Grade 1/2 Cytokine release syndrome20
SecondaryRate of Treatment Discontinuation Due to Treatment-emergent Adverse Events (TEAEs)

TEAEs are defined as adverse events that are possibly, probably, or definitely related to study treatment and occur on or after first dose of study treatment..

Time frame:
Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
Reported as:
Count of participants · Participants
Rate of Treatment Discontinuation Due to Treatment-emergent Adverse Events (TEAEs)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Rate of Treatment Discontinuation Due to Treatment-emergent Adverse Events (TEAEs)3
SecondaryPercentage of Patients Requiring Any Tocilizumab Doses for Management of Cytokine Release Syndrome (CRS)

Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.

Time frame:
Up to approximately 1 year and 3 days
Reported as:
Count of participants · Participants
Percentage of Patients Requiring Any Tocilizumab Doses for Management of Cytokine Release Syndrome (CRS)
ParticipantsMosunetuzumab and Polatuzumab Vedotin
Percentage of Patients Requiring Any Tocilizumab Doses for Management of Cytokine Release Syndrome (CRS)1
SecondaryNumber of Tocilizumab Doses Per Patient for Management of Cytokine Release Syndrome (CRS)

Tocilizumab is recommended for treatment of grade 2 CRS and required for grade 3 or 4 CRS. Tocilizumab should be administered by IV infusion for a maximum of 4 doses.

Time frame:
Up to approximately 1 year and 3 days
Reported as:
Number · dose of tocilizumab
Number of Tocilizumab Doses Per Patient for Management of Cytokine Release Syndrome (CRS)
dose of tocilizumabMosunetuzumab and Polatuzumab Vedotin
Number of Tocilizumab Doses Per Patient for Management of Cytokine Release Syndrome (CRS)1
SecondaryProgression-free Survival (PFS)

Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.

Time frame:
At 24 months

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS)

Progression-free survival is defined from the time from study enrollment to the first occurrence of disease progression as determined by the investigator with use of the Lugano Response Criteria or death from any cause.

Time frame:
At 48 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

Overall survival is defined from the time from study enrollment to death from any cause.

Time frame:
At 24 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

Overall survival is defined from the time from study enrollment to death from any cause.

Time frame:
At 48 months

Results for this outcome have not been posted.

SecondaryDuration of First Response of Complete Response (CR) or Partial Response (PR)

Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)

Time frame:
Through completion of follow-up (estimated to be 6 years)

Results for this outcome have not been posted.

SecondaryDuration of First Complete Response (CR)

Response determined by PET-CT per the Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. Response assessment is performed after cycle 2 (estimated to be day 42), after cycle 8 (estimated to be at 6 months), and at end of treatment (estimated to be 1 year)

Time frame:
Through completion of follow-up (estimated to be 6 years)

Results for this outcome have not been posted.

SecondaryTime to Next Treatment (TTNT)

Time to next treatment (TTNT) initiation is defined as the time from study enrollment to the first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy, or immunotherapy) after completion of study treatment.

Time frame:
Through completion of follow-up (estimated to be 6 years)

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were evaluated from the start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first. Total time: Up to1 year and 30 days. All-cause mortality was assessed for median follow-up of 984 days, full range 483-1323 days. Anticipated duration is up to 6 years at final results reporting.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mosunetuzumab and Polatuzumab Vedotin0/34 (0%)11/34 (32.4%)34/34 (100%)
Most frequent serious events
Most frequent serious events
EventMosunetuzumab and Polatuzumab Vedotin
Cytokine release syndromeImmune system disorders3/34
Febrile neutropeniaBlood and lymphatic system disorders1/34
Abdominal painGastrointestinal disorders1/34
DiarrheaGastrointestinal disorders1/34
Infusion site extravasationGeneral disorders1/34
Upper respiratory infectionInfections and infestations1/34
Neutrophil count decreasedInvestigations1/34
Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/34
Pregnancy lossPregnancy, puerperium and perinatal conditions1/34
PneumonitisRespiratory, thoracic and mediastinal disorders1/34
Most frequent other events
Showing 10 of 123
Most frequent other events
EventMosunetuzumab and Polatuzumab Vedotin
Lymphocyte count decreasedInvestigations29/34
Injection site reactionGeneral disorders24/34
FatigueGeneral disorders18/34
LDH increasedInvestigations18/34
NauseaGastrointestinal disorders17/34
Cytokine release syndromeImmune system disorders17/34
ConstipationGastrointestinal disorders16/34
DiarrheaGastrointestinal disorders16/34
AnemiaBlood and lymphatic system disorders14/34
RashSkin and subcutaneous tissue disorders14/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mosunetuzumab and Polatuzumab Vedotin
Mean63.1 (29 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Mosunetuzumab and Polatuzumab Vedotin
Female16
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mosunetuzumab and Polatuzumab Vedotin
Hispanic or Latino0
Not Hispanic or Latino34
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mosunetuzumab and Polatuzumab Vedotin
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White30
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Mosunetuzumab and Polatuzumab Vedotin
United States34
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2025, 34 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 151 non-industry phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 110. This study's 34 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 8, 2022
StartActual
Oct 24, 2022
Primary completionActual
Sep 18, 2025
CompletionEst.
Apr 24, 2029
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of participants with complete responseParticipants With Complete Response (CR) as best responseBest ResponseTime frame: Through completion of treatment (estimated to be 1 year)
Oct 28, 2026
Documents
Secondary outcomes
27 edited
What changed in the outcomes
  • EditedNumber of participants with complete responseParticipants With Complete Response (CR)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
  • EditedNumber of participants with partial responseParticipants With Partial Response (PR)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
  • EditedNumber of participants with partial responseParticipants With Partial Response (PR) as Best ResponseTime frame: Through completion of treatment (estimated to be 1 year)
  • EditedOverall response rateResponse Rate (ORR) as measuredMeasured by numberNumber of participants with complete responseParticipants With Complete Response (CR) and partial responsePartial Response (PR)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
  • EditedOverall response rateResponse Rate (ORR) as measuredMeasured by numberNumber of participants with complete responseParticipants With Complete Response (CR) and partial responsePartial Response (PR)Time frame: Through completion of treatment (estimated to be 1 year)
  • EditedNumber of participants with stable diseaseParticipants With Stable Disease (SD)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
  • EditedNumber of participants with stable diseaseParticipants With Stable Disease (SD) as Best ResponseTime frame: Through completion of treatment (estimated to be 1 year)
  • EditedNumber of participants with progressive diseaseParticipants With Progressive Disease (PD)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
  • EditedNumber of participants with progressive diseaseParticipants With Progressive Disease (PD) as Best ResponseTime frame: Through completion of treatment (estimated to be 1 year)
  • EditedNumber of participants with complete responseParticipants With Complete Response (CR)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
  • EditedNumber of participants with partial responseParticipants With Partial Response (PR)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
  • EditedOverall response rateResponse Rate (ORR) as measuredMeasured by numberNumber of participants with complete responseParticipants With Complete Response (CR) and partial responsePartial Response (PR)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
  • EditedNumber of participants with stable diseaseParticipants With Stable Disease (SD)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
  • EditedNumber of participants with progressive diseaseParticipants With Progressive Disease (PD)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
  • EditedProgression-free survivalSurvival (PFS)Time frame: At 24 months
  • EditedProgression-free survivalSurvival (PFS)Time frame: At 48 months
  • EditedOverall survivalSurvival (OS)Time frame: At 24 months
  • EditedOverall survivalSurvival (OS)Time frame: At 48 months
  • EditedTime to first responseFirst Response of complete responseComplete Response (CR) or partial responsePartial Response (PR)Time frame: Through completion of treatment (estimated to be 1 year)
  • EditedDuration of first response of complete responseTime to First Complete Response (CR) or partial response (PR)Time frame: Through completion of treatment (estimated to be 1 year)
  • EditedTime to first complete responseDuration of First Response of Complete Response (CR) or Partial Response (PR)Time frame: Through completion of treatment (estimated to be 1 year) → Through completion of follow-up (estimated to be 6 years)
  • EditedDuration of first complete responseFirst Complete Response (CR)Time frame: Through completion of treatment (estimated to be 1 year) → Through completion of follow-up (estimated to be 6 years)
  • EditedTime to next treatmentNext Treatment (TTNT)Time frame: Through completion of follow-up (estimated to be 6 years)
  • EditedFrequencies and gradesGrades of treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs)Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
  • EditedRate of treatment discontinuation dueTreatment Discontinuation Due to treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs)Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
  • EditedPercentage of patients requiring any tocilizumab dosesPatients Requiring Any Tocilizumab Doses for managementManagement of cytokine release syndromeCytokine Release Syndrome (CRS)Time frame: Up to approximately 1 year and 3 days
  • EditedNumber of tocilizumab doses per patientTocilizumab Doses Per Patient for managementManagement of cytokine release syndromeCytokine Release Syndrome (CRS)Time frame: Up to approximately 1 year and 3 days
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of participants with complete responseParticipants With Complete Response (CR) as best responseBest ResponseTime frame: Through completion of treatment (estimated to be 1 year)
    Secondary outcomes 27 edited
    What changed in the outcomes
    • EditedNumber of participants with complete responseParticipants With Complete Response (CR)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
    • EditedNumber of participants with partial responseParticipants With Partial Response (PR)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
    • EditedNumber of participants with partial responseParticipants With Partial Response (PR) as Best ResponseTime frame: Through completion of treatment (estimated to be 1 year)
    • EditedOverall response rateResponse Rate (ORR) as measuredMeasured by numberNumber of participants with complete responseParticipants With Complete Response (CR) and partial responsePartial Response (PR)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
    • EditedOverall response rateResponse Rate (ORR) as measuredMeasured by numberNumber of participants with complete responseParticipants With Complete Response (CR) and partial responsePartial Response (PR)Time frame: Through completion of treatment (estimated to be 1 year)
    • EditedNumber of participants with stable diseaseParticipants With Stable Disease (SD)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
    • EditedNumber of participants with stable diseaseParticipants With Stable Disease (SD) as Best ResponseTime frame: Through completion of treatment (estimated to be 1 year)
    • EditedNumber of participants with progressive diseaseParticipants With Progressive Disease (PD)Time frame: After Cycle 8 (each cycle is 21 days; estimated to be 6 months)
    • EditedNumber of participants with progressive diseaseParticipants With Progressive Disease (PD) as Best ResponseTime frame: Through completion of treatment (estimated to be 1 year)
    • EditedNumber of participants with complete responseParticipants With Complete Response (CR)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
    • EditedNumber of participants with partial responseParticipants With Partial Response (PR)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
    • EditedOverall response rateResponse Rate (ORR) as measuredMeasured by numberNumber of participants with complete responseParticipants With Complete Response (CR) and partial responsePartial Response (PR)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
    • EditedNumber of participants with stable diseaseParticipants With Stable Disease (SD)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
    • EditedNumber of participants with progressive diseaseParticipants With Progressive Disease (PD)Time frame: After Cycle 2 (each cycle is 21 days; estimated to be 42 days)
    • EditedProgression-free survivalSurvival (PFS)Time frame: At 24 months
    • EditedProgression-free survivalSurvival (PFS)Time frame: At 48 months
    • EditedOverall survivalSurvival (OS)Time frame: At 24 months
    • EditedOverall survivalSurvival (OS)Time frame: At 48 months
    • EditedTime to first responseFirst Response of complete responseComplete Response (CR) or partial responsePartial Response (PR)Time frame: Through completion of treatment (estimated to be 1 year)
    • EditedDuration of first response of complete responseTime to First Complete Response (CR) or partial response (PR)Time frame: Through completion of treatment (estimated to be 1 year)
    • EditedTime to first complete responseDuration of First Response of Complete Response (CR) or Partial Response (PR)Time frame: Through completion of treatment (estimated to be 1 year) → Through completion of follow-up (estimated to be 6 years)
    • EditedDuration of first complete responseFirst Complete Response (CR)Time frame: Through completion of treatment (estimated to be 1 year) → Through completion of follow-up (estimated to be 6 years)
    • EditedTime to next treatmentNext Treatment (TTNT)Time frame: Through completion of follow-up (estimated to be 6 years)
    • EditedFrequencies and gradesGrades of treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs)Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
    • EditedRate of treatment discontinuation dueTreatment Discontinuation Due to treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs)Time frame: Evaluated from start of treatment to 30 day follow-up after conclusion of treatment, study discontinuation/termination, or initiation of alternative lymphoma-directed therapy, whichever occurs first (estimated to be 1 year and 30 days).
    • EditedPercentage of patients requiring any tocilizumab dosesPatients Requiring Any Tocilizumab Doses for managementManagement of cytokine release syndromeCytokine Release Syndrome (CRS)Time frame: Up to approximately 1 year and 3 days
    • EditedNumber of tocilizumab doses per patientTocilizumab Doses Per Patient for managementManagement of cytokine release syndromeCytokine Release Syndrome (CRS)Time frame: Up to approximately 1 year and 3 days
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05410418
Collaborators
Genentech, Inc., Institute for Follicular Lymphoma
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Oct 24, 2022
Primary completion
Sep 18, 2025
Completion
Apr 24, 2029 (estimated)
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

David A Russler-Germain, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin

Start the discussion